Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24311892 | 0.94 | MMP2 (0.34) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL14511428 | 0.94 | MMP2 (0.38) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL19400738 | 0.94 | MMP2 (0.38) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL13792257 | 0.92 | MMP2 (0.41) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL14511415 | 0.92 | MMP2 (0.41) | MMP2CA12CA1CA2CA9 | |
| SCHEMBL24153004 | 0.87 | PIK3CD (0.37) | MMP2MMP1MMP3MMP9MMP14 | |
| SCHEMBL24312151 | 0.87 | PIK3CD (0.37) | MMP2MMP1MMP3MMP9MMP14 | |
| SCHEMBL10207365 | 0.80 | ALOX5 (0.33) | ALOX5MMP2CA12CA1CA2 | |
| SCHEMBL24667724 | 0.78 | ALOX5 (0.32) | ALOX5MMP2CA12CA1CA2 | |
| SCHEMBL21843796 | 0.78 | ALOX5 (0.41) | ALOX5MMP2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029359-B2 | Heteroaryl Btk inhibitors | BIOGEN IDEC MA, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157442-A1 | HETEROARYL BTK INHIBITORS | BTK, LYN, SYK | ALOX5 3259/4885MMP2 4341/4885CA12 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.